<DOC>
	<DOCNO>NCT01551602</DOCNO>
	<brief_summary>The objective study investigate pharmacokinetics , safety , tolerability AK159 administer healthy postmenopausal woman .</brief_summary>
	<brief_title>Clinical Study AK159 Healthy Postmenopausal Women</brief_title>
	<detailed_description>This study consist Part 1 Part 2 . &lt; Part 1 &gt; Part 1 conduct accord single-centre , randomize , single-dose , 3-period , 5-treatment alternate crossover design two group healthy post-menopausal woman The pharmacokinetics , safety , tolerability single dose AK159 ( 4 level ) investigate versus teriparatide acetate injection control . &lt; Part 2 &gt; Part 2 conduct accord multiple-centre , randomize , double-blind , placebo-controlled , repeat dose parallel design healthy post-menopausal woman The pharmacokinetics , safety , tolerability AK159 ( 4 level ) 8 week investigate versus teriparatide acetate injection placebo control . Pharmacokinetics , safety , tolerability follow long-term application also investigate .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Healthy postmenopausal ethnic Japanese woman ; At least 45 year age time consent obtain ; Give voluntary consent write sufficient understanding study . Clinical abnormality identify laboratory test Weight &lt; 40.0 kg Body mass index &lt; 17.5 &gt; =30.5 History disease kidney , liver , heart , brain , organ make ineligible subject Previously receive radiation treatment potentially affect bone Systolic blood pressure &lt; 90 mmHg QTc exceed 470 msec 12lead electrocardiography Serum calcium level exceed 10.4 mg/dL History contact dermatitis skin disease potentially compromise study evaluation Used drug impact bone metabolism 8week period precede investigational product administration Used bisphosphonate ; Used teriparatide product ;</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>AK159</keyword>
	<keyword>teriparatide acetate</keyword>
</DOC>